New Drug Approved for Deadly Lung Condition, First in Over a Decade

Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

The clearance makes Jascayd the first new drug for idiopathic pulmonary fibrosis in over a decade, but some analysts see it as a “modest” advance in care.

Boehringer bags FDA okay for new pulmonary fibrosis drug

Boehringer's successor to blockbuster IPF therapy Ofev has been approved by the FDA as Jascayd, but will the new drug be a commercial success?

Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF

Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression. The post Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF appeared first on MedCity News.

New Drug Approved for Deadly Lung Condition, First in Over a Decade

(MedPage Today) -- The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday. Primary support for the preferential...

Boehringer Ingelheim Gains FDA Approval for Jascayd, Marking a New Era in Idiopathic Pulmonary Fibrosis Treatment

More than a decade after launching one of the first therapies for idiopathic pulmonary fibrosis (IPF), Boehringer Ingelheim has secured FDA approval for its new drug Jascayd (nerandomilast), revitalizing the treatment landscape for this deadly lung disease. Jascayd becomes the first new IPF therapy since Boehringer’s Ofev and Roche’s Esbriet were approved in 2014. Clinical trials demonstrated that Jascayd, an oral twice-daily treatment, signific…

FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment.